Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310

NCT01586364 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT01586364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01586364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310
Lead sponsor
Shionogi
Phase
Phase 3
Overall status
Completed
Start date
May 8, 2006
Completion date
December 22, 2008
Enrollment
301 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrophy, vaginal diseases